Verastem files for orphan disease status for VS-6063 in mesothelioma Verastem filed an orphan drug designation for VS-6063. Verastem is seeking orphan drug designation in the US and the EU for the use of VS-6063 in mesothelioma. VS-6063 is anticipated to enter a potentially pivotal study in mesothelioma midyear 2013. Orphan designation grants US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval and 10 years of market exclusivity in member states of the EU if received.
News For VSTM From The Last 14 Days
Check below for free stories on VSTM the last two weeks.
Verastem appoints Robert Forrester as CEO Verastem will name Robert Forrester COO and a Director, and Christoph Westphal, M.D., Ph.D., Chairman and CEO, will be transitioning to Executive Chairman. These changes will be effective on July 1.